Addiction (General)
Ibogaine interrupts physical dependence across multiple substances, resetting brain reward circuits. Most effective for opioid use disorder with 50–80% abstinence rates.
Learn MoreHeroin Addiction
A single ibogaine session can eliminate acute heroin withdrawal within 24–48 hours. Long-term cravings are dramatically reduced, offering a critical window for recovery.
Learn MoreAlcohol & Stimulants
Ibogaine shows measurable benefits for alcohol dependence and stimulant (cocaine, methamphetamine) use disorders by restoring neurological balance and reducing compulsive use.
Learn MorePTSD
Ibogaine produces deep introspective states that allow processing of traumatic memories. Clinical data show significant PTSD symptom reduction after a single treatment session.
Learn MoreVeteran PTSD
Stanford and MAPS research highlight dramatic improvements in veteran populations, with reductions in PTSD severity, suicidality, and disability ratings after ibogaine treatment.
Learn MoreDepression
Ibogaine promotes neuroplasticity and BDNF expression, producing rapid antidepressant effects. Patients with treatment-resistant depression often report sustained mood improvements.
Learn MoreAnxiety
By facilitating deep psychological processing and resetting stress-response pathways, ibogaine can reduce chronic anxiety, including generalized and social anxiety disorders.
Learn MoreTraumatic Brain Injury
Emerging research shows ibogaine may promote neuroregeneration and reduce TBI-related symptoms including cognitive impairment, headaches, and mood dysregulation.
Learn MoreCymbalta Interaction
Cymbalta (duloxetine) requires a careful taper before ibogaine treatment. This guide covers the required washout period, risks, and safe transition protocols.
Learn MoreChronic Pain
A neutral review of what is — and is not — known about ibogaine and chronic pain, covering the single published neuropathic pain case report, the analgesic research on iboga-derived analogues, and the cardiac risks that dominate the safety picture. No controlled trials exist, and no trial of ibogaine for chronic pain has been registered.
Learn MoreParkinson's Disease
A neutral review of what is — and is not — known about ibogaine and Parkinson's disease, covering the single 2026 case report, the GDNF hypothesis, and the randomised trials in which GDNF itself failed. No controlled trial of ibogaine in Parkinson's has been conducted, and the cardiac risk profile is serious.
Learn MoreSuboxone (Buprenorphine) Dependence
A neutral review of what is — and is not — known about ibogaine and buprenorphine (Suboxone) dependence, covering the clearance protocols clinics use, the published opioid detoxification cohorts, and the overdose and cardiac risks that dominate the safety picture. No controlled trial has ever enrolled buprenorphine-maintained patients, and stopping opioid agonist treatment carries a documented mortality risk of its own.
Learn MoreGambling Addiction
A neutral review of what is — and is not — known about ibogaine and gambling disorder, covering the behavioural-addiction hypothesis, the evidence-based treatments that already exist, and the cardiac and psychiatric risks involved. No published clinical study of ibogaine for gambling disorder exists; the case rests entirely on mechanistic reasoning and anecdote.
Learn MoreMultiple Sclerosis
A neutral review of what is — and is not — known about ibogaine and multiple sclerosis, covering the single published case report, the GDNF and neuroinflammation hypotheses, and the cardiac risks that dominate the safety picture. No controlled trials exist; the evidence base is preliminary and does not support ibogaine as an MS treatment.
Learn MoreHow Ibogaine Works Across Conditions
Ibogaine's broad therapeutic reach stems from its unique action on multiple neurotransmitter systems simultaneously — opioid receptors, serotonin transporters, NMDA receptors, and sigma receptors. This multi-target mechanism explains why it addresses such a wide range of conditions from addiction to trauma to mood disorders.